Balchem Corporation develops, manufactures, and markets specialty ingredients and performance products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally. The company is headquartered in New Hampton, New York.
119 articles
Financial data from ICE Data Services reports Balchem Corp's pretax income on the Hannover Stock Exchange. The company trades under ticker BL9B, though the market is currently closed with no active tr
Balchem Corp (HAN:BL9B) financial data regarding total non-operating income is presented on the Hannover Stock Exchange, sourced from ICE Data Services and FactSet.
Balchem Corporation scheduled a conference call for October 23, 2026, to discuss third-quarter financial results. CEO Ted Harris and CFO Martin Bengtsson will host the event, with financial data relea
Balchem Corporation will showcase its branded ingredients and scientific leadership at SupplySide Global 2026, highlighting new research on health-focused compounds and GLP-1 companion products for fo
Balchem Corporation, a specialty chemicals firm in human and animal nutrition, releases updated financial metrics and analyst insights. The report details stock performance relative to the S&P 500 alo
Balchem published a whitepaper exploring DNA methylation's role in cellular health throughout life. The paper identifies nutrient gaps and highlights the growing market for methyl-donating ingredients
Balchem Corp disclosed its cash flow from investing activities on the Hannover Stock Exchange. Market data indicates the trading platform currently shows no active trades.
Balchem Corp (HAN:BL9B) operating cash flow data is listed on the Hannover Stock Exchange, where the market is currently closed with no trades recorded. Data is supplied by ICE Data Services and FactS
Balchem Corporation reported total revenue of 883.06 million EUR last year, with its Human Nutrition and Health segment leading performance. The United States served as the primary regional market, co
Balchem Corporation disclosed net income before discontinued operations, tracked under the Hannover Stock Exchange symbol BL9B. The report details financial metrics including value and change over spe
Balchem Corporation's SVP and Chief R&D Officer Ren Anthony Gonzalez disclosed share holdings, revealing that most direct shares are restricted stock vesting over one to three years.
Argus Research raised its price target for Balchem Corporation to $185.00 from $167.84, noting the company's development of specialty performance ingredients for various industries.
A Discounted Cash Flow analysis indicates Balchem Corporation is undervalued by roughly 25%, supported by $177.6 million in trailing twelve-month free cash flow. Capacity expansion offers upside, thou
Balchem announced research from the University of Arkansas showing Optifolin+ significantly enhances cellular DNA methylation and SAM levels. These findings support the ingredient's role in epigenetic
Balchem Corporation announced that key executives, including CEO Ted Harris, will attend the 9th Annual Wells Fargo Consumer Conference on September 23, 2026. The company specializes in developing and
Balchem Corp reported 18.70 billion MXN in annual revenue, with its Human Nutrition and Health segment contributing the majority at 11.89 billion MXN. The United States was the top regional market, ge
Balchem Corporation outlines strategies for manufacturers to meet rising protein demand in meat snacks, noting opportunities from GLP-1 trends and the use of MeatShure® microencapsulated acids.
Balchem Corporation reported strong Q2 2026 financial results, sparking debate over whether its stock is fully valued. With a P/E ratio of 34.3x exceeding the US Chemicals industry average, investors
Balchem Corporation reported strong Q2 2026 results with higher sales and net income, completing a $55.49 million share repurchase. Management confidence is evident, though risks regarding product inn
Balchem Corp, a chemicals company, reported Q2 2026 earnings with an 11.2% sales growth across all three segments. The update includes current stock performance and analyst ratings for investors.
Balchem released Q2 2026 results and a buyback update, with analysts estimating the stock is 16% undervalued driven by a new microencapsulation facility. High P/E ratios suggest potential valuation ri
H.C. Wainwright raised Balchem's price target to $215 following Q2 2026 results that exceeded revenue and earnings estimates, citing consistent growth and 16 consecutive years of dividend increases.
Balchem Corporation reported record quarterly revenue and adjusted EBITDA, yet its stock gained only 3% despite strong profitability trends. Analysts note the high 34.1x P/E ratio requires further eva
Balchem Corporation reported $1.04 billion USD in annual revenue, led by its Human Nutrition and Health segment. The United States contributed the majority of sales, totaling $759.45 million.
Balchem Corp reported record consolidated sales of $284 million and adjusted EBITDA of $78 million for Q2 2026, driven by growth in Animal and Human Nutrition segments despite higher input costs.
Balchem Corporation reported Q2 2026 revenue of $284.0 million, an 11% increase driven by its Human Nutrition and Health segment. Adjusted earnings of $1.49 per share beat estimates, though the stock
Balchem Corporation reported strong Q2 2026 financial results, exceeding consensus estimates with $1.49 adjusted earnings per share and $284 million in revenue. Growth was driven by robust demand for
Balchem Corporation reported record Q2 fiscal 2026 financial results, with net sales increasing 11.2% year-over-year to $284.0 million. The company posted GAAP net earnings of $44.6 million and genera
Balchem Corporation reported record Q2 2026 net sales of $284.0 million, an 11.2% increase year-over-year. The company amended its credit agreement and repurchased $29 million in stock reflecting conf
Balchem Corporation reported second-quarter adjusted earnings per share of $1.49, exceeding analyst expectations of $1.40. The results indicate strong profitability for the specialty ingredients manuf
ChemBrief